Newsbenzinga
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results
· Published
Article summary
Biogen beats Q3 estimates, narrows FY2026 EPS outlook, and sees analysts raise price targets to $290; shares dip 0.3% premarket.
An excerpt from the original article.
Comments —
Loading comments…